Apidra Caution For Usage

Incompatibilities: Subcutaneous use: In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products except NPH human insulin.
When used with an insulin infusion pump, Apidra must not be mixed with other medicinal products.
Intravenous use: Apidra was found to be incompatible with Glucose 5% solution and Ringer's solution and, therefore, must not be used with these solution fluids. The use of other solutions has not been studied.
Special precautions for disposal and other handling: Subcutaneous use: Apidra vials are for use with insulin syringes with the corresponding unit scale and for use with an insulin pump system (see Dosage & Administration).
Inspect the vial before use. It must only be used if the solution is clear, colourless, with no solid particles visible. Since Apidra is a solution, it does not require resuspension before use.
Insulin label must always be checked before each injection to avoid medication errors between insulin glulisine and other insulins (see Precautions).
Mixing with insulins: When mixed with NPH human insulin, Apidra should be drawn into the syringe first. Injection should be given immediately after mixing as no data are available regarding the mixtures made up a significant time before injection.
Continuous subcutaneous infusion pump: Refer to Dosage & Administration and Precautions for advice.
Intravenous use: Apidra should be used at a concentration of 1 Unit/mL insulin glulisine in infusion systems with sodium chloride 9 mg/mL (0.9%) solution for infusion with or without 40 mmol/L potassium chloride using coextruded polyolefin/polyamide plastic infusion bags with a dedicated infusion line. Insulin glulisine for intravenous use at a concentration of 1 Unit/mL is stable at room temperature for 48 hours. After dilution for intravenous use, the solution should be inspected visually for particulate matter prior to administration. It must only be used if the solution is clear and colourless, not when cloudy or with visible particles.
Apidra was found to be incompatible with Glucose 5% solution and Ringer's solution and, therefore, must not be used with these solution fluids. The use of other solutions has not been studied.